## Management of Elevated ICP in Severe Head Injury **Key Point:** Elevated intracranial pressure (ICP >20 mmHg) in head injury is associated with poor outcome. Management focuses on preventing secondary brain injury through a stepwise, evidence-based approach. ### ICP Management Hierarchy ```mermaid flowchart TD A[Elevated ICP >20 mmHg]:::urgent --> B[Tier 1: Basic measures]:::action B --> C[Head elevation 30°, normothermia, normoxia]:::action B --> D[Adequate sedation & analgesia]:::action C --> E{ICP controlled?}:::decision E -->|No| F[Tier 2: Osmotic therapy]:::action F --> G[Mannitol 0.25-1 g/kg IV or 3% hypertonic saline]:::action E -->|Yes| H[Continue monitoring]:::outcome G --> I{ICP controlled?}:::decision I -->|No| J[Tier 3: Advanced measures]:::action J --> K[Mild hyperventilation, CSF drainage, sedation escalation]:::action ``` ### Tier 1: Non-Pharmacological Measures **High-Yield:** These are the foundation of ICP management and should be initiated immediately: - **Head-of-bed elevation to 30°** — promotes cerebral venous drainage, reduces ICP without compromising cerebral perfusion pressure (CPP) - **Normothermia** — maintain 36.5–37.5°C; each 1°C rise increases cerebral metabolic rate by ~7% - **Normoxia and normocarbia** — avoid hypoxia (PaO₂ <60 mmHg) and hypercarbia - **Adequate sedation and analgesia** — reduces agitation and ICP surges - **Avoid noxious stimuli** — suctioning, repositioning can cause ICP spikes **Clinical Pearl:** Head elevation is one of the most effective and safest first-line maneuvers; it has no systemic side effects and is always appropriate. ### Tier 2: Osmotic Therapy **Key Point:** Osmotic agents are the pharmacological first-line for acute ICP elevation: - **Mannitol** — 0.25–1 g/kg IV bolus; onset 15–30 min, duration 4–6 hours - **Hypertonic saline (3%)** — 250 mL bolus; equally effective, may have fewer rebound effects - Both reduce ICP by creating an osmotic gradient that draws fluid from the brain parenchyma into the intravascular space ### Tier 3: Advanced Measures (Only if Tier 1 & 2 Fail) **Warning:** Hyperventilation is **NOT** a first-line agent. It is reserved for acute, life-threatening ICP elevation or herniation as a **temporizing measure** only. **High-Yield:** Hyperventilation mechanism and limitations: - **Mechanism:** Reduces PaCO₂ → cerebral vasoconstriction → reduced cerebral blood volume (CBV) → reduced ICP - **Target PaCO₂:** 30–35 mmHg (NOT 25–30 mmHg as a routine measure) - **Duration of effect:** Only 24–48 hours due to CSF bicarbonate buffering - **Rebound effect:** ICP often rebounds when hyperventilation is discontinued - **Cerebral ischemia risk:** Hyperventilation reduces cerebral blood flow and can worsen outcome if used chronically - **Current evidence:** Routine hyperventilation is **NOT recommended** as a first-line ICP-lowering strategy; it should be used only for acute herniation or as a bridge to definitive therapy **Mnemonic:** **HOP-M** — Head elevation, Osmotic therapy, Positioning, Mannitol (remember these BEFORE hyperventilation). ### Why Hyperventilation is NOT First-Line | Factor | Hyperventilation | | --- | --- | | Onset | Rapid (minutes) | | Duration | Short (24–48 hours) | | Rebound ICP | Yes, significant | | Cerebral blood flow | Reduced (risk of ischemia) | | Role in modern ATLS/neurocritical care | Acute emergency measure only, not routine | | Recommended target PaCO₂ | 30–35 mmHg (not 25–30) | **Clinical Pearl:** The statement targets PaCO₂ of 25–30 mmHg, which is excessively low and not recommended. Even the "emergency" use of hyperventilation targets 30–35 mmHg. [cite:ATLS 10e Ch 4; Neurocritical Care Society Guidelines on ICP Management; Harrison 21e Ch 445]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.